HIMS
Hims & Hers Health, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 42.7 reflects a company that scores well on directional momentum (17.0) and growth (14.0) but is meaningfully penalized by weak profitability, poor financial health, and zero scores in dividend and theme categories.
- The momentum sub-score of 17.0 — near the top of the 0-20 range — is the single strongest contributor to the score, anchoring the company above the lowest-tier rankings despite its structural weaknesses.
- The model's confidence of 7.0 out of 10 indicates that 7 of 10 core metrics were successfully mapped from the 10-K filing, providing a relatively complete picture of the company's financial standing and lending credibility to the 42.7 score.
Why Not Higher
- The financial health sub-score of 6.0 is a significant anchor on the overall score, reflecting leverage and balance sheet metrics from the 10-K that suggest the company's capital structure carries elevated risk that the model penalizes heavily.
- The profitability sub-score of 9.2 indicates that margin and return-on-asset metrics have not yet reached levels that would reward the model with a meaningfully higher composite score, despite the company's strong revenue growth trajectory.
Data Confidence
7 / 10
High — most data fields present
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Hims & Hers Health, Inc. is a U.S.-based direct-to-consumer telehealth platform operating in the specialty and generic drug manufacturing space, offering personalized health and wellness products across categories including sexual health, hair loss, mental health, and weight management. The company has scaled rapidly as a subscription-driven healthcare brand, leveraging its digital-first model to reach consumers who historically faced barriers to traditional healthcare access. Its FY 2025 10-K data reflects a business in active growth mode, with the model assigning a composite score of 42.7/100 — driven primarily by its momentum sub-score of 17.0 and growth sub-score of 14.0, signaling that sequential improvements in revenue and earnings trends are real and measurable. However, weak profitability (9.2), strained financial health (6.0), a zero dividend score, and no identifiable macro theme exposure dragged the overall score down considerably, reflecting the structural tradeoffs of a high-burn, high-growth healthcare platform. The central research tradeoff for HIMS is that it exhibits meaningful top-line and operational momentum — consistent with an aggressive growth profile — but has not yet translated that growth into durable profitability or a resilient balance sheet, leaving the risk profile firmly in the Very High category and the research label at Monitor Only.
Plain English
Hims & Hers is a telehealth company that sells prescription and wellness products online — think hair loss treatments, ED medications, and weight loss drugs — directly to consumers via subscriptions. The model score of 42.7 out of 100 means the company shows real growth and improving momentum from its filings, but it still struggles to turn revenue into consistent profits, and its balance sheet carries meaningful financial strain. The Very High risk rating signals that this is not a stable, established business — it's a fast-moving, loss-tolerant growth play where outcomes could swing dramatically in either direction. Researchers treating this as a potential candidate should understand they are looking at an early-stage profitability story with significant execution risk.
Bull Case vs. Bear Case
Bull Case
- The momentum sub-score of 17.0 out of 20 — the highest in the model — indicates strong sequential improvement in revenue, earnings, and margins as reported in the FY 2025 10-K, suggesting the business trajectory is accelerating rather than stalling.
- The growth sub-score of 14.0 reflects meaningful year-over-year expansion in revenue and top-line metrics, consistent with Hims & Hers' aggressive subscriber acquisition strategy and expansion into high-demand categories like GLP-1 weight management treatments.
- The best scoring profile for this company is aggressive growth at 59.1, suggesting that researchers focused on high-growth, pre-profitability business models would find the filing data most aligned with that investment thesis.
Bear Case
- The profitability sub-score of only 9.2 out of 20 indicates that net margins, operating margins, and return on assets remain weak relative to peers, meaning the company has yet to demonstrate it can convert its revenue scale into sustainable earnings.
- The financial health sub-score of 6.0 out of 20 — the weakest fundamental metric in the model — points to elevated leverage, constrained interest coverage, or balance sheet characteristics that introduce meaningful downside risk if growth slows or capital markets tighten.
- The dividend sub-score of 0.0 and theme sub-score of 0.0 confirm that the company generates no shareholder returns through distributions and lacks identifiable macro tailwind exposures that the scoring model can credit, limiting its appeal to income-focused or thematic research mandates.
What Could Change the Picture
Bullish Triggers
- Sustained improvement in operating and net margins — as would be reflected in future 10-K filings — would lift the profitability sub-score from its current 9.2 and push the composite score materially higher, potentially upgrading the research label from Monitor Only.
- A demonstrated reduction in leverage ratios and improvement in interest coverage, as shown in future balance sheet data, would strengthen the financial health sub-score from 6.0 and reduce the Very High risk rating, broadening the research audience for this candidate.
Bearish Triggers
- A deceleration in sequential revenue or earnings improvement — which would reduce the momentum sub-score from its current 17.0 — would remove the primary pillar supporting the current composite score and call into question the growth narrative embedded in the research thesis.
- Evidence in future filings of deteriorating cash flow coverage, increased debt load, or worsening interest coverage ratios would further depress the already-low financial health sub-score of 6.0, potentially triggering a downgrade in both the research label and risk rating.
Red Flags
- The financial health sub-score of 6.0 out of 20 is a material concern, suggesting the balance sheet may carry leverage or interest coverage metrics that leave limited buffer if operating cash flows deteriorate.
- A profitability sub-score of 9.2 indicates that despite rapid revenue growth, margins remain thin or negative, raising the question of whether the business model can reach self-sustaining profitability without continued capital raises.
- The gap between the aggressive growth best-fit score (59.1) and the overall model score (42.7) illustrates that even within its most favorable framing, this company scores only modestly, reflecting the breadth of its financial weaknesses across multiple dimensions.
Risk Profile
Very High RiskThe Very High risk rating for Hims & Hers reflects a combination of weak financial health (sub-score 6.0), unproven profitability at scale (sub-score 9.2), and the inherent volatility of a direct-to-consumer telehealth model operating in a competitive and regulatory-sensitive environment. Researchers should treat this as a high-uncertainty candidate where the range of potential outcomes — from strong profitability inflection to capital structure stress — is unusually wide.
Key Catalysts to Watch
The primary catalyst to watch is whether the company's strong sequential momentum (sub-score 17.0) translates into durable margin expansion and positive net income in upcoming 10-K filings, which would confirm the growth-to-profitability inflection thesis. Secondary catalysts include any regulatory developments affecting compounded or generic drug access — particularly in GLP-1 and other high-growth therapeutic categories — as these could significantly alter the company's revenue trajectory and financial health metrics.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.